» Articles » PMID: 17021749

P53 Protein Accumulation As a Prognostic Marker in Sporadic Colorectal Cancer

Overview
Date 2006 Oct 6
PMID 17021749
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aims: p53 protein plays a crucial role in the pathogenesis of a large number of malignancies. In this study, our goal was to elucidate the prognostic role of p53 overexpression and its relationship to clinicopathological variables in colorectal cancer.

Materials And Methods: Between 1999 and 2004, surgical specimens of 258 patients who received surgical treatment for colorectal cancer at the Veterans General Hospital, Taipei were collected. p53 expression in tumor tissue was evaluated by immunohistochemical analysis using the human p53-specific mouse monoclonal antibody, PAb 1801.

Results: Of the 258 patients, 97 (37.6%) had overexpression of p53 in tumor tissues. The accumulation of p53 protein in tumor tissues did not correlate with age, gender, preoperative serum carcinoembryonic antigen (CEA) level, mucin content, nodal status, and tumor stage. A statistically significant correlation was found between p53 overexpression and location of the tumor in the rectum (p=0.038). Well to moderately differentiated tumors had significantly higher frequency of p53 overexpression than poorly differentiated tumors (40.0 vs 20.0%, p=0.050). Each patient was followed up for a minimum of 2 years (median 35 months). In univariate analysis, 3-year cancer-specific survival rate was significantly higher in patients with tumor p53 overexpression (88.2%) than in patients without overexpression (log rank test, p=0.037). However, in multivariate analysis, the tumour node metastasis stage remained the most significant independent prognostic factor.

Conclusion: The accumulation of p53 protein might have a favorable prognostic value in colorectal cancer, but it is not an independent prognostic factor.

Citing Articles

Evaluation of enterotoxigenic Bacteroides fragilis correlation with the expression of cellular signaling pathway genes in Iranian patients with colorectal cancer.

Dadgar-Zankbar L, Shariati A, Bostanghadiri N, Elahi Z, Mirkalantari S, Razavi S Infect Agent Cancer. 2023; 18(1):48.

PMID: 37644520 PMC: 10463534. DOI: 10.1186/s13027-023-00523-w.


Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer.

Williams D, Mouradov D, Browne C, Palmieri M, Elliott M, Nightingale R Mod Pathol. 2019; 33(3):483-495.

PMID: 31471586 DOI: 10.1038/s41379-019-0353-2.


The roles of p53 and XPO1 on colorectal cancer progression in Yemeni patients.

Aladhraei M, Al-Salami E, Poungvarin N, Suwannalert P J Gastrointest Oncol. 2019; 10(3):437-444.

PMID: 31183193 PMC: 6534720. DOI: 10.21037/jgo.2019.01.17.


The association of p53 expression levels with clinicopathological features and prognosis of patients with colon cancer following surgery.

Cao D, Ou X, Yu T Oncol Lett. 2017; 13(5):3538-3546.

PMID: 28521456 PMC: 5431169. DOI: 10.3892/ol.2017.5929.


Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?.

Osumi H, Shinozaki E, Suenaga M, Kumekawa Y, Ogura M, Ozaka M BMC Cancer. 2015; 15:760.

PMID: 26490659 PMC: 4618932. DOI: 10.1186/s12885-015-1751-6.


References
1.
Pereira H, Silva S, Juliao R, Garcia P, Perpetua F . Prognostic markers for colorectal cancer: expression of P53 and BCL2. World J Surg. 1997; 21(2):210-3. DOI: 10.1007/s002689900218. View

2.
Ahnen D, Feigl P, Quan G, Lovato L, Bunn Jr P, Stemmerman G . Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res. 1998; 58(6):1149-58. View

3.
Soong R, Grieu F, Robbins P, Dix B, Chen D, Parsons R . p53 alterations are associated with improved prognosis in distal colonic carcinomas. Clin Cancer Res. 1997; 3(8):1405-11. View

4.
Adrover E, Maestro M, Sanz-Casla M, del Barco V, Cerdan J, Fernandez C . Expression of high p53 levels in colorectal cancer: a favourable prognostic factor. Br J Cancer. 1999; 81(1):122-6. PMC: 2374355. DOI: 10.1038/sj.bjc.6690660. View

5.
Hassan A, Paraskeva C . Colorectal cancer prognosis: is it all mutation, mutation, mutation?. Gut. 2005; 54(9):1209-11. PMC: 1774661. DOI: 10.1136/gut.2005.070946. View